Duyuru • 2h
Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update On June 15, 2026, the Company announced that the Phase 3 KOASTAL-2 and -3 studies of navacaprant for the treatment of major depressive disorder (“MDD”) did not achieve statistical significance on the primary or key secondary endpoints and that the Company is discontinuing development of navacaprant. Neumora continues to focus on advancing its potential best-in-class clinical portfolio with near-term anticipated milestones: NMRA-511 (V1a receptor antagonist, Alzheimer’s disease agitation): Complete multiple ascending dose cohort evaluating higher doses in healthy elderly volunteers in the fourth quarter of 2026. Data from this study will inform dose selection for a Phase 2b dose ranging study that the Company plans to initiate by the end of 2026. NMRA-898 (M4 positive allosteric modulator, schizophrenia): Report data from the ongoing Phase 1 study in the second half of 2026. NMRA-215 (NLRP3 inhibitor, obesity):Complete repeat 13-week rat toxicology study mid-2026 and provide a program update with the Company’s second quarter financial results in August 2026. Initiate clinical studies by year end 2026. Neumora announced that it will reduce its workforce by approximately 35%, which it expects to result in an annualized cost savings of approximately $10 million, partially offset by one-time restructuring costs of approximately $2 million. The Company expects its current cash and cash equivalents to provide runway into the third quarter of 2027, including multiple expected key clinical milestones. The KOASTAL-2 and -3 studies enrolled 430 and 422 adult patients with MDD, respectively. In addition to these topline results, Neumora announced results from pre-specified analyses of 426 patients from both studies who were enrolled following study optimizations in early 2025. The primary endpoint of both KOASTAL-2 and -3 was change from baseline (CFB) to week 6 on the Montgomery-Åsberg Depression Rating Scale (MADRS). In the KOASTAL-2 study patients treated with navacaprant 80 mg (n = 217) demonstrated a similar CFB to those treated with placebo (n = 213) [-12.2 vs -12.0; least-squares mean difference (LSMD) = -0.3; p = 0.813]. In the KOASTAL-3 study patients treated with navacaprant 80 mg (n = 212) demonstrated a numerically lower CFB than those treated with placebo (n = 210) [-10.1 vs -10.8; LSMD = 0.7; p = 0.480]. In patients enrolled after study optimizations, patients treated with navacaprant (n=216) demonstrated a similar CFB to those treated with placebo (n = 210) [-12.1 vs -12.1; LSMD = 0.0; p = 0.976]. Navacaprant was shown to be safe and generally well tolerated with a safety profile consistent with prior studies. New Risk • Jun 12
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$193m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$193m free cash flow). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$185m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Duyuru • Apr 21
Neumora Therapeutics, Inc., Annual General Meeting, May 27, 2026 Neumora Therapeutics, Inc., Annual General Meeting, May 27, 2026. Duyuru • Mar 16
Neumora Therapeutics, Inc. to Report Q4, 2025 Results on Mar 30, 2026 Neumora Therapeutics, Inc. announced that they will report Q4, 2025 results on Mar 30, 2026 New Risk • Jan 08
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m. Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$209m). Currently unprofitable and not forecast to become profitable over next 3 years (US$235m net loss in 3 years). New Risk • Nov 14
New minor risk - Financial position The company has less than a year of cash runway based on its current free cash flow. Free cash flow: -US$209m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$209m). Currently unprofitable and not forecast to become profitable over next 3 years (US$228m net loss in 3 years). Share price has been volatile over the past 3 months (15% average weekly change). Price Target Changed • Oct 27
Price target increased by 16% to US$8.17 Up from US$7.05, the current price target is an average from 6 analysts. New target price is 205% above last closing price of US$2.68. Stock is down 77% over the past year. The company is forecast to post a net loss per share of US$1.40 next year compared to a net loss per share of US$1.53 last year. New Risk • Jul 24
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$205m net loss in 3 years). Price Target Changed • Jul 23
Price target decreased by 14% to US$6.05 Down from US$7.05, the current price target is an average from 6 analysts. New target price is 227% above last closing price of US$1.85. Stock is down 84% over the past year. The company is forecast to post a net loss per share of US$1.44 next year compared to a net loss per share of US$1.53 last year. Duyuru • Jul 23
Neumora Therapeutics, Inc. to Report Q2, 2025 Results on Aug 06, 2025 Neumora Therapeutics, Inc. announced that they will report Q2, 2025 results on Aug 06, 2025 Duyuru • Jul 09
Neumora Therapeutics, Inc. Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861 Neumora Therapeutics, Inc. announced the initiation of a Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study of NMRA-861 in healthy adult participants and adults with stable schizophrenia. NMRA-861 is a highly potent and selective positive allosteric modulator (PAM) of the M4 muscarinic receptor with potential best-in-class pharmacology that Neumora is developing for the treatment of schizophrenia and other neuropsychiatric disorders. Neumora expects to report data from the Phase 1 SAD/MAD study in the first quarter of 2026, including safety and tolerability, and human pharmacokinetic data confirming the potential for once-daily dosing and central nervous system penetration. Neumora exclusively licensed certain intellectual property rights related to NMRA-861 from the Warren Center for Neuroscience Drug Discovery at Vanderbilt University, including a composition of matter patent extending to 2044 excluding any patent term adjustment or extension. While most current antipsychotics approved for schizophrenia work primarily by blocking D2 dopamine receptors, growing evidence supports the approach of targeting the M4 muscarinic receptors to elicit antipsychotic effects, without the side effects associated with the first- and second-generation antipsychotics. M4 muscarinic receptor-targeting compounds have shown robust antipsychotic activity in multiple, placebo-controlled clinical trials, demonstrating potential as an approach to treating schizophrenia. NMRA-86 1 has demonstrated a best-in-class pre-clinical profile in studies which were completed at the Warren Center for Neuroscience Drug discovery at Vanderbilt University. New Risk • Jun 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$205m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change). Duyuru • May 17
Neumora Therapeutics Receives Written Notice from the Nasdaq Stock Market On May 14, 2025, Neumora Therapeutics, Inc. (the “Company”) received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Global Select Market, as set forth in Listing Rule 5450(a)(1). In accordance with Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until November 10, 2025, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company’s common stock must meet or exceed $1.00 per share for a minimum of ten consecutive business days during this 180-day period. If the Company is not in compliance by November 10, 2025, the Company may be eligible for additional time to regain compliance. To qualify, the Company would be required to submit an application to transfer to The Nasdaq Capital Market, which would require the Company to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, except for the minimum bid price requirement. In addition, the Company would be required to pay an application fee to Nasdaq and notify Nasdaq of its intent to cure the minimum bid price deficiency. If the Company does not regain compliance within the allotted compliance periods, including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Company’s common stock will be subject to delisting. The Company would then be entitled to appeal Nasdaq’s determination, but there can be no assurance that Nasdaq would grant the Company’s request for continued listing. The Company intends to monitor the closing bid price of its common stock and consider options to resolve the noncompliance with the minimum bid price requirement, including effecting a reverse stock split of its common stock. As described in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 29, 2025, the Company’s Board of Directors (the “Board”) has approved and, subject to stockholder approval, adopted amendments to its Amended and Restated Certificate of Incorporation to effect a reverse stock split to all of the outstanding shares of its common stock at a ratio ranging from any whole number between 1-for-5 and 1-for-30, with the exact ratio within such range to be determined by the Board at its discretion (the “Reverse Stock Split”), subject to the Board’s authority to determine when to file the amendment and to abandon the other amendments notwithstanding prior stockholder approval of such amendments. Stockholders will vote on the proposal related to the Reverse Stock Split at the Company’s Annual Meeting of Stockholders on May 28, 2025. One of the purposes of the Reverse Stock Split and the related proposal is potentially maintaining the listing of the Company’s common stock on The Nasdaq Global Select Market. There can be no assurance that stockholders will approve the Reverse Stock Split or that the Company will be able to regain compliance with the minimum bid price requirement or will otherwise be in compliance with other Nasdaq listing criteria. New Risk • May 15
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: US$99.5m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$219m net loss in 3 years). Market cap is less than US$100m (US$99.5m market cap). Duyuru • Apr 28
Neumora Therapeutics, Inc. to Report Q1, 2025 Results on May 12, 2025 Neumora Therapeutics, Inc. announced that they will report Q1, 2025 results on May 12, 2025 Duyuru • Apr 14
Neumora Therapeutics, Inc., Annual General Meeting, May 28, 2025 Neumora Therapeutics, Inc., Annual General Meeting, May 28, 2025. Price Target Changed • Apr 04
Price target decreased by 11% to US$6.29 Down from US$7.04, the current price target is an average from 8 analysts. New target price is 754% above last closing price of US$0.74. Stock is down 95% over the past year. The company is forecast to post a net loss per share of US$1.46 next year compared to a net loss per share of US$1.53 last year. Duyuru • Feb 14
Michael Milligan to Serve as Chief Financial Officer of Neumora Therapeutics, Inc., Effective February 14, 2025 Neumora Therapeutics, Inc. announced that effective February 14, 2025, Michael Milligan will serve as chief financial officer. Duyuru • Feb 07
Rosen Law Firm Files Securities Class Action Lawsuit Against Neumora Therapeutics, Inc Rosen Law Firm announced it has filed a class action lawsuit on behalf of purchasers of the common stock of Neumora Therapeutics, Inc. pursuant and/or traceable to the registration statement and related prospectus (collectively, the Offering Documents) issued in connection with Neumora’s September 2023 initial public offering. The lawsuit seeks to recover damages for Neumora investors under the federal securities laws. According to the lawsuit, the Offering Documents contained false and/or misleading statements and/or failed to disclose that: in order for Neumora to justify conducting its Phase Three Program, Neumora was forced to amend BlackThorn’s original Phase Two Trial inclusion criteria to include a patient population with moderate to severe MDD to show that Navacaprant offered a statistically significant improvement in treating MDD; and to that same end, the Company also added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD; and the Phase Two Trials lacked adequate data, particularly in regards to the patient population size and the ratio of male to female patients within the patient population, to be able to accurately predict the results of the KOASTAL-1 study. When the true details entered the market, the lawsuit claims that investors suffered damages. A class action lawsuit has already been filed. If wish to serve as lead plaintiff, must move the Court no later than April 7, 2025. Price Target Changed • Jan 02
Price target decreased by 18% to US$19.10 Down from US$23.33, the current price target is an average from 9 analysts. New target price is 870% above last closing price of US$1.97. Stock is down 88% over the past year. The company is forecast to post a net loss per share of US$1.57 next year compared to a net loss per share of US$3.63 last year. Duyuru • Jan 02
Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder Neumora Therapeutics, Inc. announced results from the Phase 3 KOASTAL-1 Study of navacaprant for the treatment of major depressive disorder (MDD). The KOASTAL-1 Study is the first of three replicate Phase 3 studies that comprise the pivotal KOASTAL program. The study did not demonstrate a statistically significant improvement on the primary endpoint of change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Week 6 or the key secondary endpoint of a change from baseline in the Snaith-Hamilton Pleasure Scale (SHAPS) scale. Navacaprant was shown to be safe and generally well-tolerated with no serious adverse events reported. There was no signal for increased suicidal ideation or suicidal behavior compared to placebo, as measured by Columbia Suicide Severity Rating Scale (C-SSRS). The KOASTAL program includes three replicate Phase 3 randomized, placebo-controlled, double-blind studies, KOASTAL-1, KOASTAL-2, and KOASTAL-3, designed to evaluate the efficacy and safety of navacaprant monotherapy in adult patients with moderate-to-severe MDD who have a MADRS total score = 25 at baseline. The KOASTAL-1 Study was conducted in the U.S. The KOASTAL-2 and -3 studies include sites in the U.S. and other regions. The primary endpoint of these studies is change from baseline in MADRS total score at Week 6. Key secondary endpoints include change from baseline on the SHAPS at Week 6, a measure of anhedonia. The KOASTAL Program also includes an open-label extension study, KOASTAL-LT, designed to evaluate the long-term safety of navacaprant. As noted above, a significant portion of patients who received navacaprant 80 mg (83.3%) in the KOASTAL-1 study elected to enroll in KOASTAL-LT. Patients will also have the opportunity to enroll in the KOASTAL-LT study following participation in the KOASTAL-2 and KOASTAL-3 studies. New Risk • Nov 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$255m net loss in 3 years). Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (4.8% increase in shares outstanding). Duyuru • Oct 29
Neumora Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Neumora Therapeutics, Inc. announced that they will report Q3, 2024 results on Nov 12, 2024 Recent Insider Transactions Derivative • Oct 20
Independent Director exercised options and sold US$244k worth of stock On the 18th of October, Matthew Fust exercised 22k options at a strike price of around US$2.52 and sold these shares for an average price of US$13.72 per share. This trade did not impact their existing holding. Since June 2024, Matthew has not owned shares directly. This was the only transaction from an insider over the last 12 months. Duyuru • Oct 02
Neumora Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $300 million. Neumora Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.
Security Name: Common Stock
Security Type: Common Stock
Transaction Features: At the Market Offering Recent Insider Transactions Derivative • Sep 15
Head of Research & Development notifies of intention to sell stock Robert Lenz intends to sell 33k shares in the next 90 days after lodging an Intent To Sell Form on the 12th of September. If the sale is conducted around the recent share price of US$11.43, it would amount to US$377k. As of today, Robert currently holds no shares directly (This sale likely refers to shares that have not yet been received). There has only been one transaction (US$189k purchase) from insiders over the last 12 months. Recent Insider Transactions Derivative • Aug 25
Chief Financial Officer notifies of intention to sell stock Joshua Pinto intends to sell 100k shares in the next 90 days after lodging an Intent To Sell Form on the 22nd of August. If the sale is conducted around the recent share price of US$11.90, it would amount to US$1.2m. Since September 2023, Joshua has owned 238.97k shares directly. There has only been one transaction (US$189k purchase) from insiders over the last 12 months. Duyuru • Jun 20
Neumora Therapeutics, Inc. Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer’s Disease Agitation Neumora Therapeutics, Inc. announced the initiation of a Phase 1b study evaluating NMRA-511 for the treatment of agitation associated with dementia due to Alzheimer’s disease (AD). NMRA-511 is an oral, highly potent and selective antagonist of the vasopressin 1a receptor (V1aR) and is highly brain penetrant. Modulation of the V1aR is known to play a role in the regulation of aggression, stress and anxiety responses. The Phase 1b study will investigate NMRA-511 initially in healthy elderly adult participants and then people with agitation associated with dementia due to AD. Part A of the Phase 1b study will be a randomized, double-blind, placebo-controlled cohort designed to evaluate the safety, tolerability and pharmacokinetics of NMRA-511 in approximately 8 healthy elderly participants. Part B of the Phase 1b study is a multicenter, randomized, double-blind, placebo-controlled, parallel-group cohort designed to evaluate the safety, tolerability, and efficacy of NMRA-511 20 mg twice-daily (BID) in approximately 88 people with agitation associated with dementia due to AD. The primary endpoint of this signal-seeking study is change from baseline to Week 8 on the Cohen-Mansfield Agitation Inventory total score. Neumora expects to report topline data from this Phase 1b study in the second half of 2025. Several lines of evidence indicate that V1aR antagonists have therapeutic potential for reducing symptoms of agitation. Pre-clinically, multiple models have demonstrated that activating the vasopressin system with the endogenous agonist AVP modulates social-emotional, anxiety and threat-related behaviors across species. In rodents, the selective breeding of strains for aggressive or anxiety traits show dysregulated vasopressin release and hypothalamic-pituitary-adrenal axis functioning. Additionally, vasopressin-deficient rodents displayed impaired responses to threat stimuli, reduced anxiety and depressive-like behaviors, and impaired aggression toward intruders. Clinically, in healthy volunteers, exogenously administered vasopressin increased autonomic responsiveness to threat stimuli and increased anxiety. Conversely, V1aR antagonist administration suppressed anxiety induced by unpredictable threats. This finding is in line with data showing that concentrations of vasopressin in cerebrospinal fluid were positively correlated with levels of aggression in individuals with personality disorders. Together, these data support the development of a V1aR antagonist for the treatment of symptoms of agitation, aggression, and anxiety. Neumora recently completed a Phase 1a Single Ascending Dose (SAD) /Multiple Ascending Dose (MAD) study that evaluated 5,10, 15, 20 and 40 mg doses of NMRA-511 in 92 healthy adult participants. NMRA-511 was generally well tolerated across doses in the study, with no serious adverse events observed at any dose level. The Company looks forward to sharing additional data from the SAD /MAD study with NMRA-511 at future medical meetings. Duyuru • May 15
Neumora Therapeutics, Inc. Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression Neumora Therapeutics, Inc. announced the initiation of a Phase 2 study evaluating the safety and efficacy of navacaprant in people with bipolar depression. Navacaprant is an oral 80 mg once-daily best-in-class kappa opioid receptor (KOR) antagonist, a novel mechanism of action in development for the treatment of major depressive disorder (MDD) and bipolar depression. The randomized, double-blind, placebo-controlled, Phase 2 clinical trial is designed to evaluate the safety and efficacy of navacaprant in people with depression associated with bipolar II disorder. The study will evaluate navacaprant 80 mg monotherapy in approximately 60 patients with a moderate-to-severe major depressive episode (Montgomery–Åsberg Depression Rating Scale (MADRS) = 25). The primary endpoint of the study is change in MADRS at Week 6, and key secondary endpoints will evaluate the impact of navacaprant on anhedonia as well as other measures. Neumora expects to report topline data from this Phase 2 study in the second half of 2025. Results from this proof-of-concept study will inform further development of navacaprant in bipolar disorder, potentially including development in broader bipolar disorder populations. Duyuru • Apr 28
Neumora Therapeutics, Inc., Annual General Meeting, Jun 13, 2024 Neumora Therapeutics, Inc., Annual General Meeting, Jun 13, 2024, at 08:30 US Eastern Standard Time. Agenda: To elect two Class I directors to hold office until the 2027 annual meeting of stockholders or until their successors are elected; To ratify the appointment, by the Audit Committee of the Company’s Board of Directors, of Ernst & Young LLP, as the independent registered public accounting firm and independent auditor of the Company for its year ending December 31, 2024. Duyuru • Apr 15
Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study Neumora Therapeutics, Inc. announced that the Phase 1 trial of NMRA-266 has been placed on clinical hold by the U.S. Food and Drug Administration (FDA). NMRA-266 is a positive allosteric modulator (PAM) of the M4 muscarinic receptor and is part of the Company’s M4 PAM franchise. The clinical hold determination follows recently available pre-clinical data showing convulsions in rabbits. Following this action, the Phase 1 single ascending dose /multiple ascending dose study with NMRA-266 has been paused. Approximately 30 participants have been dosed in the Phase 1 study, with no evidence of convulsions observed in any participant. Neumora is working with the FDA to evaluate the potential to resolve the clinical hold. While these discussions with the Agency are ongoing, the Company’s prior guidance regarding NMRA-266 is no longer applicable. Neumora will provide an update on NMRA-266 when available. Neumora’s M4 franchise includes multiple novel compounds beyond NMRA-266 that each have different properties and chemical composition. These compounds demonstrated robust activity in preclinical efficacy models, as well as high selectivity for the M4 receptor subtype and the potential for an oral once-daily dosing profile. Neumora is advancing pre-clinical safety and toxicology work with these compounds and expects to submit an IND in 2025. New Risk • Mar 10
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 0.2% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 0.2% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$282m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Duyuru • Jan 23
Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer Neumora Therapeutics, Inc. announced the appointment of Kaya Pai Panandiker as chief commercial officer and a member of Neumora’s executive team, reporting to Henry Gosebruch, president and chief executive officer. Ms. Pai Panandiker has more than 20 years of experience commercializing medicines in areas of significant unmet need, including the commercial launches of TRINTELLIX® (vortioxetine) and REXULTI® (brexpiprazole) for major depressive disorder (MDD) and schizophrenia. Ms. Pai Panandiker brings extensive commercial strategy and execution expertise to Neumora, having led the launches of multiple neuropsychiatry products throughout her career. Prior to joining Neumora, Ms. Pai Panandiker served as head of commercial at Cerevel Therapeutics and general manager, neuroscience at Lundbeck US. During her time at Lundbeck, Ms. Pai Panandiker led commercialization efforts for its neuroscience franchise, achieving blockbuster sales. Ms. Pai Panandiker holds a master’s in public policy from University of Chicago and a bachelor's in American studies from University of Wisconsin Madison. Duyuru • Dec 12
Neumora Therapeutics, Inc. Appoints Jason Duncan as Chief Legal Officer Neumora Therapeutics, Inc. announced the appointment of Jason Duncan as chief legal officer. Mr. Duncan will be a member of Neumoras Executive Team, reporting to Henry Gosebruch, chief executive officer, and will oversee all aspects of the Company's legal and compliance functions. Mr. Duncan has more than two decades of legal, compliance, development and operations experience in the life sciences industry. Prior to joining Neumora, he served as chief legal officer, general counsel, secretary to the board of directors and head of program management at Albireo Pharma, a publicly traded Boston-based biotech company that was acquired by Ipsen earlier this year. During his time at Albireo, Mr. Duncan contributed to growing the company from an early clinical stage biotech to a fully integrated commercial organization with two drug approvals and a successful global launch. Prior to Albireo, Mr. Duncan served as general counsel, Americas at Stallergenes Greer Holdings and vice president, head of compliance and legal, North America at Sobi, Inc. Earlier in his career Mr. Duncan held roles at EMD Serono, Inc., Acushnet Company, Nixon Peabody LLP and Peabody &Arnold LLP. Mr. Duncan holds a J.D., magna cum laude, from Suffolk University Law School and a B.A. in Political Science from Dickinson College. Duyuru • Nov 29
Neumora Therapeutics, Inc. Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study Neumora Therapeutics, Inc. announced the initiation of a Phase 1 single ascending dose /multiple ascending dose study evaluating NMRA-266 in healthy adult participants. NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor that Neumora is developing as a treatment for schizophrenia and other neuropsychiatric disorders. Neumora believes that as a selective M4 receptor-positive allosteric modulator, NMRA-266 has the potential to deliver antipsychotic efficacy, while minimizing the side effects associated with current antipsychotics and other non-selective muscarinic agonists. Duyuru • Sep 16
Neumora Therapeutics, Inc. has completed an IPO in the amount of $250.07 million. Neumora Therapeutics, Inc. has completed an IPO in the amount of $250.07 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 14,710,000
Price\Range: $17
Transaction Features: Sponsor Backed Offering 
